MTOR and cancer: Dysregulation of the PI3K/AKT/mTOR pathway is recognized as a marker of cancer development and gene alterations associated with this pathway are frequently observed in TNBC.[16] Overactivation of the PI3K/AKT/mTOR pathway supports the hypothesis that targeting this signaling pathway may provide a beneficial therapeutic strategy.